inclusion criteria: male or females aged ≥ 18 years moderately ill patients with covid-19 (defined as ordinal scale of 5 or 6): hospitalized, requiring supplemental oxygen or hospitalized, on non-invasive ventilation or high flow oxygen devices evidence of pneumonia (pulmonary infiltrates) at chest radiography or computed tomography compatible with covid-19. hospitalization for less than 72 hours, receiving standard of care treatment for covid-19. laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by polymerase chain reaction (pcr). subject (or legally authorized representative) provides written or oral informed consent prior to initiation of any study procedures. women of childbearing potential and their partner must agree to use at least one highly effective method of contraception (e.g., hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], intrauterine devices, bilateral tubal occlusion, or sexual abstinence) for the duration of the study.

inclusion criteria: male or females aged ≥ 18 years moderately ill patients with covid-19 (defined as ordinal scale of 5 or 6): hospitalized, requiring supplemental oxygen or hospitalized, on non-invasive ventilation or high flow oxygen devices evidence of pneumonia (pulmonary infiltrates) at chest radiography or computed tomography compatible with covid-19. hospitalization for less than 72 hours, receiving standard of care treatment for covid-19. laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by polymerase chain reaction (pcr). subject (or legally authorized representative) provides written or oral informed consent prior to initiation of any study procedures. women of childbearing potential and their partner must agree to use at least one highly effective method of contraception (e.g., hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], intrauterine devices, bilateral tubal occlusion, or sexual abstinence) for the duration of the study.

inclusion criteria: 1. male or females aged ≥ 18 years 2. moderately ill patients with covid-19 (defined as ordinal scale of 5 or 6): hospitalized, requiring supplemental oxygen or hospitalized, on non-invasive ventilation or high flow oxygen devices 3. evidence of pneumonia (pulmonary infiltrates) at chest radiography or computed tomography compatible with covid-19. 4. hospitalization for less than 72 hours, receiving standard of care treatment for covid-19. 5. laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by polymerase chain reaction (pcr). 6. subject (or legally authorized representative) provides written or oral informed consent prior to initiation of any study procedures. 7. women of childbearing potential and their partner must agree to use at least one highly effective method of contraception (e.g., hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], intrauterine devices, bilateral tubal occlusion, or sexual abstinence) for the duration of the study.

inclusion criteria: 1. male or females aged ≥ 18 years 2. moderately ill patients with covid-19 (defined as ordinal scale of 5 or 6): hospitalized, requiring supplemental oxygen or hospitalized, on non-invasive ventilation or high flow oxygen devices 3. evidence of pneumonia (pulmonary infiltrates) at chest radiography or computed tomography compatible with covid-19. 4. hospitalization for less than 72 hours, receiving standard of care treatment for covid-19. 5. laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by polymerase chain reaction (pcr). 6. subject (or legally authorized representative) provides written or oral informed consent prior to initiation of any study procedures. 7. women of childbearing potential and their partner must agree to use at least one highly effective method of contraception (e.g., hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], intrauterine devices, bilateral tubal occlusion, or sexual abstinence) for the duration of the study.